AlphaMark Advisors’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $68K | Hold |
700
| – | – | 0.03% | 214 |
|
|
2024
Q3 | $81K | Sell |
700
-265
| -27% | -$30.1K | 0.03% | 300 |
|
|
2024
Q2 | $103K | Hold |
965
| – | – | 0.04% | 279 |
|
|
2024
Q1 | $93K | Buy |
965
+265
| +38% | +$27.2K | 0.03% | 285 |
|
|
2023
Q4 | $71K | Hold |
700
| – | – | 0.03% | 306 |
|
|
2023
Q3 | $71K | Hold |
700
| – | – | 0.03% | 292 |
|
|
2023
Q2 | $71K | Hold |
700
| – | – | 0.03% | 189 |
|
|
2023
Q1 | $64K | Hold |
700
| – | – | 0.03% | 209 |
|
|
2022
Q4 | $64K | Hold |
700
| – | – | 0.03% | 188 |
|
|
2022
Q3 | $53K | Hold |
700
| – | – | 0.03% | 201 |
|
|
2022
Q2 | $59K | Hold |
700
| – | – | 0.03% | 194 |
|
|
2022
Q1 | $61K | Sell |
700
-900
| -56% | -$77.9K | 0.02% | 211 |
|
|
2021
Q4 | $140K | Buy |
1,600
+1,350
| +540% | +$112K | 0.05% | 157 |
|
|
2021
Q3 | $20K | Sell |
250
-286
| -53% | -$25.7K | 0.01% | 332 |
|
|
2021
Q2 | $49K | Hold |
536
| – | – | 0.02% | 233 |
|
|
2021
Q1 | $46K | Hold |
536
| – | – | 0.02% | 238 |
|
|
2020
Q4 | $51K | Sell |
536
-275
| -34% | -$24K | 0.02% | 207 |
|
|
2020
Q3 | $71K | Hold |
811
| – | – | 0.03% | 173 |
|
|
2020
Q2 | $71K | Hold |
811
| – | – | 0.03% | 176 |
|
|
2020
Q1 | $67K | Buy |
811
+86
| +12% | +$7.67K | 0.04% | 155 |
|
|
2019
Q4 | $69K | Hold |
725
| – | – | 0.03% | 180 |
|
|
2019
Q3 | $63K | Hold |
725
| – | – | 0.03% | 186 |
|
|
2019
Q2 | $66K | Sell |
725
-84
| -10% | -$7.11K | 0.03% | 180 |
|
|
2019
Q1 | $70K | Buy |
809
+418
| +107% | +$33.6K | 0.03% | 175 |
|
|
2018
Q4 | $30K | Buy |
+391
| New | +$30.4K | 0.01% | 221 |
|
|
2016
Q1 | – | Sell |
-279
| Closed | -$22K | – | 325 |
|
|
2015
Q4 | $22K | Hold |
279
| – | – | 0.01% | 184 |
|
|
2015
Q3 | $23K | Hold |
279
| – | – | 0.01% | 168 |
|
|
2015
Q2 | $25K | Hold |
279
| – | – | 0.01% | 185 |
|
|
2015
Q1 | $25K | Hold |
279
| – | – | 0.01% | 186 |
|
|
2014
Q4 | $23K | Hold |
279
| – | – | 0.01% | 190 |
|
|
2014
Q3 | $24K | Hold |
279
| – | – | 0.02% | 194 |
|
|
2014
Q2 | $23K | Hold |
279
| – | – | 0.01% | 196 |
|
|
2014
Q1 | $21K | Sell |
279
-670
| -71% | -$48.8K | 0.01% | 190 |
|
|
2013
Q4 | $68K | Hold |
949
| – | – | 0.04% | 125 |
|
|
2013
Q3 | $65K | Hold |
949
| – | – | 0.04% | 136 |
|
|
2013
Q2 | $60K | Buy |
+949
| New | +$61.7K | 0.04% | 150 |
|
Other funds holding NVS
AlphaMark Advisors's NVS Position: Q4 2024 in Review
AlphaMark Advisors held its Novartis (NVS) position steady in Q4 2024 at 700 shares worth $68K. The position accounts for 0.03% of the portfolio, ranked #214.
AlphaMark Advisors first reported a position in NVS in Q2 2013 and has held it in 36 quarters since. The position peaked at $140K in Q4 2021. 1,341 funds tracked by Wall St. Rank hold NVS as of Q4 2024.
- AlphaMark Advisors held 700 shares of Novartis worth $68K as of Q4 2024.
- AlphaMark Advisors left its Novartis share count unchanged in Q4 2024.
- Novartis made up 0.03% of AlphaMark Advisors's portfolio in Q4 2024, its #214 holding.
- AlphaMark Advisors first reported a position in Novartis in Q2 2013 and has held it in 36 quarters since.
- AlphaMark Advisors's Novartis position peaked at $140K in Q4 2021.
- 1,341 funds tracked by Wall St. Rank held Novartis as of Q4 2024.
Based on AlphaMark Advisors's 13F filing for Q4 2024, filed 21 Jan 2025.